US Patent

US9745290 — Dosage regimen for COMT inhibitors

Method of Use · Assigned to Bial Portela and Cia SA · Expires 2027-10-10 · 1y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a dosing regimen for administering an oxodiazolyl compound to prevent or treat central and peripheral nervous system disorders.

USPTO Abstract

The invention relates to the use of an oxodiazolyl compound (I) for the preparation of a medicament for the prevention or treatment of central and peripheral nervous system associated disorders, wherein said medicament is administered according to a dosing regimen having a dosing periodicity ranging from about twice a day to about once every other day.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3869`	—
`U-3869`	—

Patent Metadata

Patent number: US9745290
Jurisdiction: US
Classification: Method of Use
Expires: 2027-10-10
Drug substance claim: No
Drug product claim: Yes
Assignee: Bial Portela and Cia SA
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.